Warning: "continue" targeting switch is equivalent to "break". Did you mean to use "continue 2"? in /home/qkzvfg3dk8y7/public_html/saarum.co.in/wp-content/plugins/siteorigin-panels/inc/styles-admin.php on line 392
admin – Saarum Sciences http://saarum.co.in Accelerating Drug Discovery Fri, 07 Aug 2020 06:46:26 +0000 en hourly 1 https://wordpress.org/?v=4.9.22 133453159 Establishment of glioma patient derived 3D cultures to evaluate the potency of drugs compared to 2D model http://saarum.co.in/blog/establishment-of-glioma-patient-derived-3d-cultures-to-evaluate-the-potency-of-drugs-compared-to-2d-model/ http://saarum.co.in/blog/establishment-of-glioma-patient-derived-3d-cultures-to-evaluate-the-potency-of-drugs-compared-to-2d-model/#respond Thu, 23 Aug 2018 11:52:17 +0000 http://saarum.co.in/?p=8584 Attended Regional Young investigator meeting, Hyderabad (18th – 19th August, 2018) at University of Hyderabad. Sapien Biosciences presented importance of primary human patient cultures, especially spheroid cultures (3D) for drug testing in Glioblastoma multiforme. We have identified molecules that demonstrated differential anti-cancer activity between 2D and 3D cultures in multiple functional readouts including inhibition of  cancer stem cells.

 

 

 

]]>
http://saarum.co.in/blog/establishment-of-glioma-patient-derived-3d-cultures-to-evaluate-the-potency-of-drugs-compared-to-2d-model/feed/ 0 8584
Our Biobank cited in cover story of India Today http://saarum.co.in/cancer-research-updates/our-biobank-cited-in-cover-story-of-india-today/ http://saarum.co.in/cancer-research-updates/our-biobank-cited-in-cover-story-of-india-today/#respond Sat, 01 Jul 2017 10:16:09 +0000 http://saarum.co.in/?p=8498 Excited to share that our Biobank at Sapien Biosciences and the patient cancer-derived cell models developed by Saarum Sciences Private Limited were covered by India Today as part of their COVER STORY devoted to innovation in India in the fight against Cancer (26th June issue). Kudos to Damayanti Datta for putting together a detailed summary for lay people to better understand the concepts and buzz words doing the rounds, and to India Today for in-depth coverage of science and healthcare. Big Thanks to Aroon Puri for citing us in the EDITOR’S NOTE as well.

 

 

 

 

 

 

 

 

]]>
http://saarum.co.in/cancer-research-updates/our-biobank-cited-in-cover-story-of-india-today/feed/ 0 8498
Dr. Jugnu Jain, Director- Apollo Research speaks about Multi-centric breast cancer database, and research initiatives to improve … http://saarum.co.in/cancer-research-updates/dr-jugnu-jain-director-apollo-research-speaks-about-multi-centric-breast-cancer-database-and-research-initiatives-to-improve/ http://saarum.co.in/cancer-research-updates/dr-jugnu-jain-director-apollo-research-speaks-about-multi-centric-breast-cancer-database-and-research-initiatives-to-improve/#respond Sat, 01 Jul 2017 04:31:18 +0000 http://saarum.co.in/?p=8476 ]]> http://saarum.co.in/cancer-research-updates/dr-jugnu-jain-director-apollo-research-speaks-about-multi-centric-breast-cancer-database-and-research-initiatives-to-improve/feed/ 0 8476 NIPER Hyderabad Pharma Industry Summit http://saarum.co.in/blog/niper-hyderabad-pharma-industry-summit/ http://saarum.co.in/blog/niper-hyderabad-pharma-industry-summit/#respond Fri, 31 Mar 2017 09:39:46 +0000 http://saarum.co.in/?p=8430 NIPER here held a Pharma Industry Summit on 24th March 2017, bringing together many govt, academic, industry and trade groups to speak about life sciences entrepreneurship in Hyd. It was a great initiative by Dr. Nanduri who himself brings many years of industrial experience to NIPER.

I particularly enjoyed the opportunity to moderate a panel discussion on “Start Up and Entrepreneurship in Life Sciences : Challenges and Way Forward”. Our panel consisted of two academics : Dr. Suman Kapoor of BITS Pilani Hyd who has brought out a device to determine TB infection much faster, and Dr. Madhusudhan of CCMB who is currently spearheading CCMB as an incubator for Life Sciences industry.  Dr. Balaji Bhyravbhatla of Hylasco, a serial entrepreneur, Dr. Swaroop Vakkalanka of Incozen with several licensing deals under his belt, and myself as a co-founder of Sapien Biosciences represented LS Industry.

Each panelist spoke from their experience and shared some of their advice such as getting sufficient experience in one’s field before embarking on entrepreneurship, assessing your market often to manage risk, knowing your investor as well as your competitors, maintaining a diary of ideas and vetting them with experienced people, not being too possessive of one’s ideas, being willing to back out if timing is not right, forming teams of 3-4 people where 1 member is not a scientist etc.

There were many questions from the audience which made for a lively interaction.

Key action items that emerged from the panel were to

a)      Form a LS group and hold a monthly networking meeting rotating at different forums several of which were offered immediately – CCMB, BITS campus, NIPER, Madhapur. A WA group will be created soon.

b)     Create a comprehensive directory of LS companies in Hyd area

I noted that I knew all the panelists! This used to be common in LS meetings at TiE-Boston but it was nice that it finally happened in Hyderabad, a city I moved to 5 years ago.

In picture from L to R: Mr S Reddy (Registrar NIPER), Dr. S Nanduri (Professor, NIPER), Dr. J Jain (CEO, Sapien), Dr. S Vakkalanka (CEO, Incozen), Dr S Kapoor (Professor BIT Pilani Hyd), Dr. B Bhyravbhatla (CEO, Hylasco), Dr. Madhusudhan (Professor, CCMB).

]]>
http://saarum.co.in/blog/niper-hyderabad-pharma-industry-summit/feed/ 0 8430
Industry Internships for Motivated Biology-Based Graduate Students http://saarum.co.in/blog/industry-internships-for-motivated-biology-based-graduate-students/ http://saarum.co.in/blog/industry-internships-for-motivated-biology-based-graduate-students/#respond Sat, 16 Jul 2016 05:44:59 +0000 http://saarum.co.in/?p=8369 Jugnu Jain
CEO at Sapien Biosciences & Saarum Sciences

We offer 2 to 12 month research internships for bright diligent motivated graduate students in Biology, Biotech, Pharmacy, Bioinformatics, Health data analytics etc. The internships can be hands-on lab experience (molecular biology, cell biology, diagnostics, FACS etc.), or in medical data analysis, sample and clinical data organization in EMR/EHR databases. Specific clinically-relevant projects focused on patient treatment paradigms e.g., breast cancer, stent procedures drugs and outcomes, cost-benefit analysis of targeted drugs are also available.

Lab-based training is available at Hyderabad, whilst data and project-based training is available at Ahmedabad, Bangalore, Bhubaneswar, Chennai, Delhi, Kolkata and other metro locations where Apollo Hospitals are present.

Appropriate ethical approval for projects involving handling of patient material or data is always taken. Students are trained in confidentiality and safety norms.

In addition to a certificate of internship and thesis, students are encouraged to present their findings in conferences. Longer-term interns that make significant contribution to projects may also be acknowledged in presentations and publications from our group. Mentoring of students aspiring for MS/PhD abroad is done on a case-by-case basis.

]]>
http://saarum.co.in/blog/industry-internships-for-motivated-biology-based-graduate-students/feed/ 0 8369
Accelerating Drug Discovery http://saarum.co.in/featured/accelerating-drug-discovery/ http://saarum.co.in/featured/accelerating-drug-discovery/#respond Sat, 14 Nov 2015 10:37:35 +0000 http://saarum.co.in/?p=8319 In this Post-Genomic era disease models are better understood from a Multi-Omics perspective

Learn more

]]>
http://saarum.co.in/featured/accelerating-drug-discovery/feed/ 0 8319
Phenotypic Drug Discovery Platforms http://saarum.co.in/featured/phenotypic-drug-discovery-platforms/ http://saarum.co.in/featured/phenotypic-drug-discovery-platforms/#respond Sat, 14 Nov 2015 10:34:55 +0000 http://saarum.co.in/?p=8317 The most efficient, cost effective and comprehensive way to Re-Purpose your drugs

Learn more

]]>
http://saarum.co.in/featured/phenotypic-drug-discovery-platforms/feed/ 0 8317
Physiologically Relevant Platforms http://saarum.co.in/featured/physiologically-relevant-platforms/ http://saarum.co.in/featured/physiologically-relevant-platforms/#respond Sat, 14 Nov 2015 10:32:19 +0000 http://saarum.co.in/?p=8315 OncoPrime is a Phenotypic Drug Discovery Platform with a full array of characterizations relevant to disease phenotype and vital for studying the drug response in native state

Learn more

]]>
http://saarum.co.in/featured/physiologically-relevant-platforms/feed/ 0 8315
Introducing OncoPrime http://saarum.co.in/featured/introducing-oncoprime/ http://saarum.co.in/featured/introducing-oncoprime/#respond Sat, 14 Nov 2015 10:29:00 +0000 http://saarum.co.in/?p=8313 Our flagship product / platform as a service for accelerating drug discovery with the help of primary cells isolated from tumor tissue biopsy

]]>
http://saarum.co.in/featured/introducing-oncoprime/feed/ 0 8313
Larger Renal Cell Carcinoma Tumors Predict High-Grade Pathology http://saarum.co.in/cancer-research-updates/larger-renal-cell-carcinoma-tumors-predict-high-grade-pathology/ http://saarum.co.in/cancer-research-updates/larger-renal-cell-carcinoma-tumors-predict-high-grade-pathology/#respond Mon, 15 Jun 2015 15:56:30 +0000 http://saarum.co.in/?p=8072 NEW ORLEANS—Larger tumor size is associated with high-grade pathology in patients with pT1a renal cell carcinoma (RCC), according to study findings presented at the 2015 American Urological Association annual meeting.

Jeffrey A. Larson, MD, of the Washington University School of Medicine in St. Louis, Mo., and colleagues identified 975 patients with T1a N0M0 RCC treated with robotic-assisted partial nephrectomy.

The clinical tumor size was 2.84 cm in patients with high-grade pathology and 2.56 cm in patients with low-grade pathology, a size difference that was statistically significant, the researchers reported.

In multivariate analysis, larger tumor size was associated with a significant 62% increased odds of high-grade pathology.

In multivariate analysis, larger tumor size was associated with a significant 62% increased odds of high-grade pathology.

In multivariate analysis, larger tumor size was associated with a significant 62% increased odds of high-grade pathology.

The study also found that male patients had a significant 66% increased odds of high-grade pathology compared with female patients and papillary RCC was associated with a significant 73% increased odds of high-grade pathology compared with clear-cell RCC.

The authors noted that, with an increased focus on the use of renal mass biopsies and surveillance of small renal masses (SRMs), the confirmation of the size to grade correlation of pT1a RCC allows urologists to predict more accurately which SRMs are appropriate to treat and which might be safely surveyed.

Source: http://www.renalandurologynews.com/aua-2015-other-genitourinary-cancers/larger-rcc-tumors-predict-high-grade-pathology/article/415171/

]]>
http://saarum.co.in/cancer-research-updates/larger-renal-cell-carcinoma-tumors-predict-high-grade-pathology/feed/ 0 8072